{"title":"Chatting with artificial intelligence to combat antibiotic resistance: Opportunities and challenges","authors":"Mohammad Abavisani , Alireza Khoshrou , Sobhan Karbas Foroushan , Amirhossein Sahebkar","doi":"10.1016/j.crbiot.2024.100197","DOIUrl":null,"url":null,"abstract":"<div><p>Antibiotic resistance (ABR) is a dire global health crisis, undermining the efficacy of antibiotics and ranking among the top ten public health threats according to the World Health Organization. Despite multifaceted efforts to tackle ABR, complex challenges persist across scientific, economic, behavioral, ethical, and legal dimensions. Artificial intelligence (AI), which encompasses machine capabilities for human-like tasks, offers a wide range of applications in healthcare. Chatbots, a subtype of AI, emerge as a powerful avenue for natural language interaction with users. In healthcare, chatbots have demonstrated value in symptom assessment, mental health support, medication adherence, and patient engagement. In this context, our article will comprehensively examine the opportunities and challenges presented by chatbots in bacterial disease management and ABR mitigation. We will delve into not only the technical considerations but also the ethical, legal, and social complexities accompanying their integration into healthcare. The current consideration will be valuable for healthcare professionals, policymakers, and researchers as they navigate the dynamic intersection of chatbots and the pressing issue of antibiotic resistance.</p></div>","PeriodicalId":52676,"journal":{"name":"Current Research in Biotechnology","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590262824000236/pdfft?md5=510a3f6da3dcf5ee6fd73f2a753f14e1&pid=1-s2.0-S2590262824000236-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590262824000236","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Antibiotic resistance (ABR) is a dire global health crisis, undermining the efficacy of antibiotics and ranking among the top ten public health threats according to the World Health Organization. Despite multifaceted efforts to tackle ABR, complex challenges persist across scientific, economic, behavioral, ethical, and legal dimensions. Artificial intelligence (AI), which encompasses machine capabilities for human-like tasks, offers a wide range of applications in healthcare. Chatbots, a subtype of AI, emerge as a powerful avenue for natural language interaction with users. In healthcare, chatbots have demonstrated value in symptom assessment, mental health support, medication adherence, and patient engagement. In this context, our article will comprehensively examine the opportunities and challenges presented by chatbots in bacterial disease management and ABR mitigation. We will delve into not only the technical considerations but also the ethical, legal, and social complexities accompanying their integration into healthcare. The current consideration will be valuable for healthcare professionals, policymakers, and researchers as they navigate the dynamic intersection of chatbots and the pressing issue of antibiotic resistance.
抗生素耐药性(ABR)是一个严峻的全球健康危机,它破坏了抗生素的疗效,被世界卫生组织列为十大公共卫生威胁之一。尽管为解决抗生素耐药性问题做出了多方面的努力,但在科学、经济、行为、伦理和法律等方面仍然存在复杂的挑战。人工智能(AI)包括机器执行类似人类任务的能力,在医疗保健领域有着广泛的应用。聊天机器人是人工智能的一个子类型,是与用户进行自然语言交互的强大途径。在医疗保健领域,聊天机器人在症状评估、心理健康支持、用药依从性和患者参与等方面都体现出了价值。在此背景下,我们的文章将全面探讨聊天机器人在细菌性疾病管理和 ABR 缓解方面带来的机遇和挑战。我们不仅将深入探讨技术方面的考虑因素,还将探讨将聊天机器人融入医疗保健的伦理、法律和社会复杂性。在医疗保健专业人员、政策制定者和研究人员探索聊天机器人与抗生素耐药性这一紧迫问题的动态交叉点时,当前的考虑将对他们很有价值。
期刊介绍:
Current Research in Biotechnology (CRBIOT) is a new primary research, gold open access journal from Elsevier. CRBIOT publishes original papers, reviews, and short communications (including viewpoints and perspectives) resulting from research in biotechnology and biotech-associated disciplines.
Current Research in Biotechnology is a peer-reviewed gold open access (OA) journal and upon acceptance all articles are permanently and freely available. It is a companion to the highly regarded review journal Current Opinion in Biotechnology (2018 CiteScore 8.450) and is part of the Current Opinion and Research (CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists' workflow.